Docket No. TIP-0054-USPCT

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Simmen et al.

Int'l Appln. No.: PCT/EP2004/052388

Serial No. : Unassigned Art Unit: Unassigned

Filed : I.A. September 30, 2004 Examiner: Unassigned

For : HCV INHIBITING SULFONAMIDES

MAIL STOP PATENT APPLICATION Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

#### INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

冈 In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified national application (other than a continued prosecution application under §1.53(d)), within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of a request for continued examination under §1.114, no additional fee is required. In accordance with §1.129(a), this Information Disclosure Statement is being filed in connection with [ ] the first or second After Final Submission, therefore: П Statement in Accordance with §1.97(e) (attached); or Please charge Deposit Account No. 10-0750/ / the fee of \$180.00 as set forth in §1.17(p). In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, or an action that otherwise closes prosecution and that it is accompanied by one of: Statement in Accordance with §1.97(e) П (attached); or Please charge Deposit Account No. 10-0750/ / the fee of \$180.00 as set forth §1.17(p). in In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of

either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee. Applicant(s) hereby petition(s) for consideration of this Information Disclosure Statement. Included are: Statement in Accordance with §1.97(e) as set forth below and the fee of \$180.00 as set forth in §1.17(p). Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith. Copies of references listed on the attached Form PTO-1449 are enclosed herewith EXCEPT THAT: In view of the voluminous nature of references  $\Box$ [list as appropriate], and the likelihood that these references are available to the Examiner, copies are not enclosed herewith. If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.  $\boxtimes$ Copies of only foreign patent documents and nonpatent literature are enclosed in accordance with 37 CFR 1.98 (a)(2). There are no listed references which are not in the 冈 English language. П The relevance of those listed references which are not in the English language is as follows:

Attached are copies of search report(s) from corresponding patent application(s), which are listed on the attached Submission Under MPEP 609 D.

Attached are the following non-published pending patent applications which may be deemed relevant, which are listed on the attached Submission Under MPEP 609 D.

Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/TIP-0054-USPCT/LAD. This form is submitted in triplicate.

Respectfully submitted,

/Laura A. Donnelly/

Laura A. Donnelly Reg. No. 38,435 Attorney for Applicants

Johnson & Johnson One Johnson & Johnson Plaza New Brunswick, NJ 08933-7003 (732) 524-1729 DATED: March 21, 2006

## SUBMISSION UNDER MPEP 609 D

Page 1 of 1

Application Number	Unassigned
Filing Date	March 21, 2006
First Named Inventor	Kenneth Alan
	Simmen
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	TIP-0054-USPCT

U.S. PATENT DOCUMENTS

			U.S. Patent Docum	nent		
Examiner Initials	Cite No.1	Name of Patentee or Applicant of Cited Document	Number	Kind Code <sup>2</sup> (if known)	Pages, Columns, Lines, where relevant passages or relevant figures appear	
		· · · · · · · · · · · · · · · · · · ·				
	1 1					
	<u> </u>					
				7 (14)		

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite	Name of Patentee or Applicant of Cited Document	Foreign Pa	atent Docume	ent KindCode <sup>5</sup>	Pages, Columns, Lines, where relevant passages or relevant figures appear	T <sup>6</sup>
				ļ			
	-		· · · · · · · · · · · · · · · · · · ·				
	<u> </u>	OTHER PRIOR ART - N	ON PATENT	LITERATUR	RE DOCUMEN	ITS	<u> </u>
Examiner 's Initials*	Cite No.1	Include name of the author (in C title of the item (book, magazine volume-issue number(s	e, journal, se	erial, sympo	osium, catalo	g, etc.), date, page(s),	T <sup>2</sup>
		International Search Report dated PCT/EP2004//052388.	March 18	, 2005 for	related Inte	emational Application No.	
						<u>-</u>	
<del></del>	<u></u>	L					

Examiner		Date		
Signature		Considered		

PTC/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 1 of 2

a concentration of the strain and the same and the strain and the			
Application Number	Unassigned		
Filing Date	March 21, 2006		
First Named Inventor	Kenneth Alan Simmen		
Group Art Unit	Unassigned		
Examiner Name	Unassigned		
Attorney Docket Number	TIP-0054-USPCT		

#### **U.S. PATENT DOCUMENTS**

				U.S. PATEITI DOCUMENTS		p
		U.S. Patent Document			Date of Publication	Pages, Columns, Lines,
Examiner Initials	Cite No. <sup>1</sup>	Number	Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant of Cited Document	of Cited Document mm-dd-yyyy	where relevant passages or relevant figures appear
		2003/0050229	A1	Sommadossi et al.	03-13-2003	
		6,514,953	В1	Armitage et al.	02-04-2003	

## FOREIGN PATENT DOCUMENTS FOREIGN PATENT DOCUMENTS

		Foreign Patent Document			Name of Patentee or	Date of Publication of Cited Document	Pages, Columns, Lines, where relevant	
Examiner Initials	Cite No. <sup>1</sup>	Office <sup>3</sup>	Number⁴ Kir	ndCode <sup>5</sup>	Applicant of Cited Document	mm-dd-yyyy	passages or relevant figures appear	T⁵
		wo	03/064416	A1	Boehringer Ingelheim International GMBH	08-07-2003		
		wo	03/053435	A1	Tibotec Pharmaceuticals Ltd.	07-03-2003		
		wo	95/06030		G.D. Searle & Co.	03-02-1995		
		,						
3								
-								
			1					

Examiner	Date	
Signature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

<sup>1</sup> Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08A (08-00) Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number,

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 2 of 2.

a collection of information diffess it displays a valid OMS control number.			
Application Number	Unassigned		
Filing Date	March 21, 2006		
First Named Inventor	Kenneth Alan Simmen		
Group Art Unit	Unassigned		
Examiner Name	Unassigned		
Attorney Docket Number	TIP-0054-USPCT		

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner's Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²
		Internet Article, 'Online!, "Management of hepatitis B and C in HIV co-infected patients", September 2003, pp. S59-S65 (XP002319203).	
		Internet Article, 'Online!, "Lack of hepatotoxicity associated with nonnucleoside reverse transcriptase inhibitors", April 2002, pp. 340-345 (XP002319202).	
		Johansson et al., "Acyl Sulfonamides as Potent Protease Inhibitors of the Hepatitis C Virus Full-Length NS3 (Protease-Helicase/NTPase): A Comparative Study of Different C-Terminals", Bioorganic & Medicinal Chemistry, vol. 11, pp. 25551-2568 (2003).	
V			<del></del>
	<u> </u>	· · · · · · · · · · · · · · · · · · ·	

Examiner	Date	
Signature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

<sup>1</sup> Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.